PuraPharm Corporation Limited (HKG:1498)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.300
0.00 (0.00%)
Apr 29, 2026, 2:38 PM HKT
-38.14%
Market Cap 160.52M
Revenue (ttm) 336.11M
Net Income (ttm) -35.22M
Shares Out 535.05M
EPS (ttm) -0.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 288,000
Average Volume 383,288
Open 0.295
Previous Close 0.300
Day's Range 0.295 - 0.300
52-Week Range 0.275 - 0.550
Beta 0.22
RSI 45.48
Earnings Date May 26, 2026

About PuraPharm Corporation

PuraPharm Corporation Limited, an investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Oncozac, Haveron, and Immuzac brand names. It also provides Chinese medicine clinic management system for general... [Read more]

Sector Healthcare
Founded 1998
Employees 469
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1498
Full Company Profile

Financial Performance

In 2025, PuraPharm Corporation's revenue was 336.11 million, a decrease of -12.03% compared to the previous year's 382.09 million. Losses were -35.22 million, -0.61% less than in 2024.

Financial Statements

News

There is no news available yet.